Lupituss SF Suspension contains Levocloperastine at a concentration of 20 mg per 5 ml and is indicated for the symptomatic relief of cough associated with upper respiratory tract infections and other non-productive cough conditions. Levocloperastine is a selective peripheral antitussive agent that acts by inhibiting the cough reflex through modulation of sensory nerve endings in the respiratory tract, without causing central nervous system depression or sedation. This makes Lupituss SF Suspension suitable for patients requiring effective cough suppression without the adverse effects commonly associated with traditional opioid antitussives. The formulation is designed for oral administration, allowing for ease of dosing in both pediatric and adult populations. It is important to adhere to the prescribed dosage and duration of therapy to ensure optimal efficacy and minimize potential side effects. Common adverse reactions are generally mild and may include gastrointestinal discomfort or allergic reactions in rare cases. Lupituss SF Suspension should be used with caution in patients with a history of hypersensitivity to Levocloperastine or any of the excipients. It is contraindicated in cases of productive cough where expectoration is necessary. Consultation with a healthcare professional is advised prior to use, especially in pregnant or lactating women and patients with underlying medical conditions.